Skip to main content
Equibles
KAYS logo

KAYS · Kaya Holdings, Inc. · Metrics

Track KAYS — free

Use KAYS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KAYS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Nov 20, 2025

Substantial doubt about the company's ability to continue as a going concern.

“These matters raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this material uncertainty.”
View the 10-Q filed Nov 20, 2025
Market Cap
$892,374
Shares
686.44M
Volume · Nov 12 2627 Avg daily vol (3M) 5336

KAYS metrics

52 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$892,374

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
-91.8%
Price change (3M)
+1,200.0%
Price change (6M)
-95.7%
Price change (YTD)
-96.7%
Price change (1Y)
-97.4%
Trailing year
Price change (5Y)
-99.0%
52-week high
$0.05
52-week low
$0.00
Change from 52-week high
-97.2%
Change from 52-week low
+1,200.0%
Annualized volatility
2,195.2%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
-17.7
RSI (14D)
46.7
Price vs SMA 50
-76.8%
Price vs SMA 200
-95.3%
Avg volume (3M)
7,151
Relative volume
0.3
Average dollar volume
$1

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
686.44M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,315.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
−$6,883
Operating profit (TTM)
−$1.14M
Net income (TTM)
−$11.74M
Trailing 12 months
Diluted EPS (TTM)
$-0.12
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.10
Book value per share
$-0.36

Growth

11 metrics
Revenue growth YoY
+80.3%
Year over year
Net income growth YoY
-229.3%
Revenue (TTM)
−$1,318
Trailing 12 months
EPS growth YoY
-800.0%
Shares change YoY
+507.6%
Year over year · more shares
Revenue CAGR (3Y)
-80.0%
Revenue CAGR (5Y)
-62.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-5,890.2%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$1.13M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$553,967
Latest balance sheet
Cash & equivalents
$26,087
Total assets
$199,358
Total debt
$580,054

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$786,140
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$684,750
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
0
13F filer change QoQ
-1
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1530746 CUSIP 486567209 Visit website